| Indicators | Browse All

Atrium Therapeutics, Inc. (RNA)

Healthcare | Biotechnology | San Diego, United States | NasdaqGS
12.44 USD +0.22 (1.800%) ⇧ (July 14, 2026, 12:04 p.m. EDT)

Short-term:★☆☆☆☆Long-term:★★⯪☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:18 a.m. EDT

The immediate outlook is severely clouded by a stark divergence between the company's narrative and market reality. While the business boasts a fortress balance sheet with minimal debt and a massive cash reserve relative to operations, the stock is trapped in a value trap with negative profitability and no dividend support. The most alarming signal is the options flow: traders are aggressively buying deep out-of-the-money puts, betting on a catastrophic failure or prolonged stagnation, while call interest is virtually non-existent. This speculative positioning suggests the market views the current rally as a 'dead cat bounce' rather than a genuine recovery. Although the 11% revenue growth and pristine capital structure provide a solid floor for a turnaround story, the lack of earnings, the negative operating margins, and the overwhelming bearish sentiment in derivatives prevent any bullish thesis from gaining traction. Until the company demonstrates a path to profitability or a catalyst that shifts the options skew, the risk-reward profile remains skewed heavily toward the downside.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.038828
AutoARIMA0.038830
MSTL0.040317
AutoTheta0.064396

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 42%
H-stat 0.98
Ljung-Box p 0.000
Jarque-Bera p 0.022
Excess Kurtosis 0.58
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.145
Revenue per Share 2.144
Market Cap 212,794,208
Forward P/E -2.13
Profit Margins -159.99%
Website https://atriumtherapeutics.com

As of July 11, 2026, 6:18 a.m. EDT: Speculators are overwhelmingly bearish, positioning massive downside protection via deep out-of-the-money puts (strikes 65-70) with significant open interest accumulation over the next 12-24 months. Conversely, call activity is negligible and concentrated in extremely distant strikes (50-75), indicating a lack of near-term bullish conviction despite the company's narrative potential.


Info Dump

Attribute Value
52 Week Change -0.17152542
Address1 10,578 Science Center Drive
Address2 Suite 125
All Time High 16.77
All Time Low 11.4
Ask 15.48
Ask Size 2
Average Daily Volume10 Day 245,180
Average Daily Volume3 Month 260,063
Average Volume 260,063
Average Volume10Days 245,180
Bid 8.79
Bid Size 2
Book Value 13.686
City San Diego
Country United States
Crypto Tradeable 0
Currency USD
Current Price 12.44
Current Ratio 13.037
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 12.44
Day Low 12.05
Debt To Equity 1.145
Display Name Atrium Therapeutics
Earnings Timestamp End 1,778,533,200
Earnings Timestamp Start 1,778,533,200
Ebitda -59,038,000
Ebitda Margins -1.60954
Enterprise To Ebitda 0.951
Enterprise To Revenue -1.53
Enterprise Value -56,138,044
Eps Current Year -3.59
Eps Forward -5.85
Eps Trailing Twelve Months -4.92
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 12.835
Fifty Day Average Change -0.39500046
Fifty Day Average Change Percent -0.03077526
Fifty Two Week Change Percent -17.152542
Fifty Two Week High 16.77
Fifty Two Week High Change -4.330001
Fifty Two Week High Change Percent -0.25819921
Fifty Two Week Low 11.4
Fifty Two Week Low Change 1.04
Fifty Two Week Low Change Percent 0.09122807
Fifty Two Week Range 11.4 - 16.77
Financial Currency USD
First Trade Date Milliseconds 1,772,202,600,000
Float Shares 15,720,941
Forward Eps -5.85
Forward P E -2.1264956
Full Exchange Name NasdaqGS
Gmt Off Set Milliseconds -14,400,000
Gross Margins -0.32911998
Gross Profits -12,072,000
Has Pre Post Market Data 1
Held Percent Insiders 0.04267
Held Percent Institutions 0.87875
Implied Shares Outstanding 17,105,643
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,026-02-27
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Long Name Atrium Therapeutics, Inc.
Market us_market
Market Cap 212,794,208
Market State REGULAR
Max Age 86,400
Message Board Id finmb_1972622727
Most Recent Quarter 1,774,915,200
Net Income To Common -58,685,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 209,030,957
Number Of Analyst Opinions 3
Open 12.26
Operating Cashflow -61,169,000
Operating Margins -0.88005996
Payout Ratio 0.0
Phone 619 876 0700
Previous Close 12.22
Price Eps Current Year -3.465181
Price Hint 2
Price To Book 0.908958
Price To Sales Trailing12 Months 5.8013687
Profit Margins -1.59992
Quick Ratio 12.913
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.21999931
Regular Market Change Percent 1.8003217
Regular Market Day High 12.44
Regular Market Day Low 12.05
Regular Market Day Range 12.05 - 12.44
Regular Market Open 12.26
Regular Market Previous Close 12.22
Regular Market Price 12.44
Regular Market Time 1,784,045,084
Regular Market Volume 134,127
Revenue Growth 11.483
Revenue Per Share 2.144
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 17,105,643
Shares Percent Shares Out 0.2138
Shares Short 3,610,418
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 3,653,605
Short Name Atrium Therapeutics, Inc.
Short Ratio 15.4
Source Interval 15
State CA
Symbol RNA
Target High Price 25.0
Target Low Price 25.0
Target Mean Price 25.0
Target Median Price 25.0
Total Cash 267,848,992
Total Cash Per Share 15.659
Total Debt 2,680,000
Total Revenue 36,680,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -4.92
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 13.302903
Two Hundred Day Average Change -0.8629036
Two Hundred Day Average Change Percent -0.06486581
Type Disp Equity
Volume 134,127
Website https://atriumtherapeutics.com
Zip 92,121